Intravitreal triamcinolone acetonide injection for acute non‐arteritic anterior ischaemic optic neuropathy *

Non‐arteritic anterior ischaemic optic neuropathy is the most common optic neuropathy of the elderly, characterised by unilateral, sudden, painless visual loss. No effective treatment has been proven to reverse or limit the course of this disease. We evaluated the role of intravitreal triamcinolone acetonide injection in eyes with non‐arteritic anterior ischaemic optic neuropathy (NAION). Four eyes of four patients with acute NAION received a single intravitreal injection of triamcinolone acetonide (4 mg). The time between visual loss and intravitreal injection varied between four and 10 days. Mean age of patients was 57.25 years (range, 44 to 77 years). All patients experienced some visual gain. No complications related to the injection were observed during the following three months. Intravitreal triamcinolone injection may offer help in limiting the damage in this small group of patients with a relatively short history of visual loss due to NAION.

[1]  Wu Luhu NON-ARTERITIC ANTERIOR ISCHAEMIC OPTIC NEUROPATHY , 2019, Key Topics in Ophthalmology.

[2]  S. Hayreh,et al.  Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. , 2008, Ophthalmology.

[3]  O. Gelisken,et al.  Intravitreal Triamcinolone Improves Recovery of Visual Acuity in Nonarteritic Anterior Ischemic Optic Neuropathy , 2007, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[4]  J. Jonas,et al.  Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[5]  Fadi A Jurdi,et al.  Intravitreal triamcinolone acetonide for the management of diabetic papillopathy. , 2004, American journal of ophthalmology.

[6]  A. Arnold Pathogenesis of nonarteritic anterior ischemic optic neuropathy. , 2003, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[7]  A. Arnold PATHOGENESIS OF NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY , 2003 .

[8]  John W. Johnson,et al.  Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group. , 1995, JAMA.

[9]  K. Joos,et al.  Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. , 1994, American journal of ophthalmology.

[10]  R. Hepler,et al.  Natural History of Nonarteritic Anterior Ischemic Optic Neuropathy , 1994, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[11]  F. Körner,et al.  Systemische Kortikosteroidtherapie bei nicht-arteriitischer anteriorer ischämischer Optikusneuropathie , 1992 .

[12]  J. Menzi,et al.  [Systemic corticosteroid therapy in non-arteritic anterior ischemic optic neuropathy]. , 1992, Klinische Monatsblätter für Augenheilkunde.

[13]  G. Sawle,et al.  The natural history of non-arteritic anterior ischaemic optic neuropathy. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[14]  J. Olver,et al.  Microvascular study of the retrolaminar optic nerve in man: The possible significance in anterior ischaemic optic neuropathy , 1990, Eye.

[15]  S S Hayreh,et al.  Anterior ischaemic optic neuropathy. III. Treatment, prophylaxis, and differential diagnosis. , 1974, The British journal of ophthalmology.

[16]  S. Hayreh,et al.  Anterior ischaemic optic neuropathy. I. Terminology and pathogenesis. , 1974, The British journal of ophthalmology.